Bellicum Pharmaceuticals, Inc.
BLCM
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -22.38M | -28.83M | -25.48M | -24.97M | -16.25M |
| Total Depreciation and Amortization | 9.00K | 8.00K | 9.00K | 11.00K | 24.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.00K | 653.00K | -1.61M | 645.00K | -5.69M |
| Change in Net Operating Assets | -500.00K | 928.00K | 1.24M | -1.47M | -2.99M |
| Cash from Operations | -22.85M | -27.24M | -25.84M | -25.78M | -24.90M |
| Capital Expenditure | -11.00K | -11.00K | -19.00K | -21.00K | -14.00K |
| Sale of Property, Plant, and Equipment | 15.00K | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 4.00K | -11.00K | -19.00K | -21.00K | -14.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | -- | -- | -- | -- | 32.91M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | 32.91M |
| Foreign Exchange rate Adjustments | -1.00K | -11.00K | -13.00K | -16.00K | -5.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -22.85M | -27.26M | -25.87M | -25.82M | 7.99M |